In addition, tasurgratinib showed antitumor activity in combination with elacestrant, a next-generation oral SERD showing significant PFS benefit in patients with ESR1-mutated breast cancer [30] in two ER+ breast cancer PDX models harboring ESR1 mutations. The gene discussed is ESR1; the disease is breast carcinoma.